STL Index for: Desloratadine

Bilastine has a proven, long-term safety record with use by over 71 million patients in over 104 countries. This article describes the evolution from first generation antihistamines, second generation antihistamines, and where Bilastine comes in.

Urticaria and angioedema and some forms of this disorder may be increasing in both prevalence and severity due to changes in medications, environment and other factors. This review focuses on a rational approach to differential diagnosis and therapy of the most common forms of urticaria and angioedema.

The elderly population is increasing and drug dosing requires special considerations for efficacy and decreasing toxicity. This overview provides algorithms for adjusting drug and dosage based on current evidence-based knowledge with emphasis on drugs prescribed in dermatological practice.

Chronic urticaria is a common dermatologic condition that is idiopathic in most cases. Antihistamines are the mainstays of treatment for this condition. The newer, second and third generation antihistamines are the preferred agents because of their improved safety profile and comparable efficacy to the first generation antihistamines.